#ntc

Milan, 16 July 2026 - NTC has successfully completed the EcoVadis 2026 assessment, a globally recognized sustainability rating that evaluates companies across environmental, social, ethical, and sustainable procurement criteria. The achievement marks

NTC S.r.l., one of the leading Italian pharmaceutical companies focused on ophthalmology, along with its main shareholder Wise Equity, announce the completion of the acquisition of Pharmathen’s ophthalmology business. The acquisition adds to NTC a co

Milan, May 18, 2026 – NTC announces the launch in Italy of a biosimilar medicine based on aflibercept, used for the treatment of retinal diseases associated with neovascularization and edema, which are among the leading causes of vision loss in the a

NTC accelerates MDR transition, certifying 65% of its medical device portfolio Milan, 24/02/2026 – NTC S.r.l. (NTC), An international pharmaceutical company headquartered in Italy, with a strong focus on ophthalmology and a significant presence in gy

Today NTC celebrates its 10th anniversary of its new journey, marking a decade of robust growth, strategic clarity and strong values. Nowadays, NTC has become one of the largest European developers and distributors of eye therapeutic solutions, spann